Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Century Therapeutics, Inc. (IPSC)
Company Research
Source: GlobeNewswire
Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308 advancing through IND-enabling studies to support planned clinical study initiation in 2026Estimated cash runway into 4Q 2027 PHILADELPHIA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “Today we announced our iPSC derived beta islet program for T1D. We have generated a compelling preclinical data package that underscores the tremendous opportunity to potentially deliver a functional cure for T1D. We are moving with urgency and anticipate initiating IND-enabling studies by the end of 2025, with a project
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Century Therapeutics (NASDAQ:IPSC) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.MarketBeat
- Century Therapeutics (NASDAQ:IPSC) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $2.00 price target on the stock, down previously from $7.00.MarketBeat
- Century Therapeutics Announces New Beta Islet Program for Type 1 DiabetesGlobeNewswire
IPSC
Earnings
- 11/13/25 - Miss
IPSC
Sec Filings
- 12/2/25 - Form DEFA14A
- 12/2/25 - Form DEF
- 11/24/25 - Form 4
- IPSC's page on the SEC website